|
AU2013341186B2
(en)
|
2012-11-08 |
2017-03-30 |
Bristol-Myers Squibb Company |
Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
|
|
JP6266639B2
(ja)
|
2012-11-08 |
2018-01-24 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
ＩＬ−１２、ＩＬ−２３および／またはＩＦＮαの調節に有用なアルキルアミド置換ピリミジン化合物
|
|
CA2890983A1
(en)
|
2012-11-08 |
2014-05-15 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyridyl compounds useful as kinase modulators
|
|
TWI582077B
(zh)
|
2013-11-07 |
2017-05-11 |
必治妥美雅史谷比公司 |
作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
|
|
ES2702126T3
(es)
|
2013-12-10 |
2019-02-27 |
Bristol Myers Squibb Co |
Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
|
|
UY35935A
(es)
|
2014-01-03 |
2015-06-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
|
|
WO2016001341A1
(en)
*
|
2014-07-03 |
2016-01-07 |
F. Hoffmann-La Roche Ag |
Sulfonylaminopyridine compounds, compositions and methods of use
|
|
WO2016022626A1
(en)
*
|
2014-08-06 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Heterocyclic cgrp receptor antagonists
|
|
TW201718571A
(zh)
|
2015-06-24 |
2017-06-01 |
必治妥美雅史谷比公司 |
經雜芳基取代之胺基吡啶化合物
|
|
AR105112A1
(es)
|
2015-06-24 |
2017-09-06 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituida con heteroarilo
|
|
UY36747A
(es)
|
2015-06-24 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
|
|
LT3380465T
(lt)
*
|
2015-11-26 |
2020-11-10 |
Novartis Ag |
Diamino piridino dariniai
|
|
EP3526222B1
(en)
|
2016-10-14 |
2022-08-17 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
WO2018111787A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Bristol-Myers Squibb Company |
Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses
|
|
EP3592746B1
(en)
|
2017-03-08 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
|
EA039189B1
(ru)
|
2017-05-11 |
2021-12-15 |
Бристол-Маерс Сквибб Компани |
Тиенопиридины и бензотиофены в качестве ингибиторов irak4
|
|
TWI776810B
(zh)
*
|
2017-05-12 |
2022-09-11 |
瑞士商諾華公司 |
新穎二胺基吡啶衍生物
|
|
WO2019023468A1
(en)
|
2017-07-28 |
2019-01-31 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
IL274816B2
(en)
*
|
2017-11-21 |
2023-12-01 |
Bristol Myers Squibb Co |
Sulfone pyridine alkyl amide-substituted heteroaryl compounds
|
|
IL315310A
(en)
*
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3752143B1
(en)
|
2018-02-13 |
2025-04-09 |
Rutgers, The State University of New Jersey |
Antibacterial agents: o-alkyl-deuterated pyronins
|
|
WO2019160875A1
(en)
|
2018-02-13 |
2019-08-22 |
Rutgers, The State University Of New Jersey |
Antibacterial agents: soluble salts and aqueous formulations of pyronins
|
|
WO2019173507A1
(en)
|
2018-03-06 |
2019-09-12 |
Rutgers, The State University Of New Jersey |
Antibacterial agents : arylalkylcarboxamido phloroglucinols
|
|
AR117398A1
(es)
|
2018-03-12 |
2021-08-04 |
Abbvie Inc |
Inhibidores de la señalización mediada por tirosina cinasa 2
|
|
JP7485609B2
(ja)
*
|
2018-03-22 |
2024-05-16 |
ブリストル－マイヤーズ スクイブ カンパニー |
ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
WO2020081508A1
(en)
|
2018-10-15 |
2020-04-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2020092196A1
(en)
*
|
2018-10-30 |
2020-05-07 |
Bristol-Myers Squibb Company |
Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
|
|
EP3886904A4
(en)
|
2018-11-30 |
2022-07-13 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
CN113271938A
(zh)
|
2018-11-30 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
CA3126034A1
(en)
|
2019-01-23 |
2020-07-30 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CN111757878B
(zh)
*
|
2019-01-28 |
2023-07-28 |
江苏豪森药业集团有限公司 |
一种哒嗪类衍生物抑制剂、其制备方法和应用
|
|
KR20220035447A
(ko)
|
2019-07-18 |
2022-03-22 |
브리스톨-마이어스 스큅 컴퍼니 |
IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물
|
|
ES2961950T3
(es)
|
2019-07-18 |
2024-03-14 |
Bristol Myers Squibb Co |
Compuestos heteroarílicos tricíclicos útiles como inhibidores de IRAK4
|
|
EP4004000B1
(en)
|
2019-07-23 |
2025-07-09 |
Bristol-Myers Squibb Company |
Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
|
|
CN114174279B
(zh)
|
2019-08-06 |
2024-07-02 |
百时美施贵宝公司 |
可用作irak4抑制剂的双环杂环化合物
|
|
KR20220105631A
(ko)
|
2019-09-13 |
2022-07-27 |
님버스 새턴 인코포레이티드 |
Hpk1 길항제 및 이의 용도
|
|
EP4100408B1
(en)
|
2020-02-03 |
2024-02-28 |
Bristol-Myers Squibb Company |
Tricyclic heteroaryl compounds useful as irak4 inhibitors
|
|
WO2021158495A1
(en)
|
2020-02-03 |
2021-08-12 |
Bristol-Myers Squibb Company |
Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
|
|
CN112203515B
(zh)
*
|
2020-03-11 |
2022-08-02 |
西北农林科技大学 |
N-苄基苯甲酰胺类化合物作为除草剂的用途
|
|
KR20230004612A
(ko)
*
|
2020-04-14 |
2023-01-06 |
고사머 바이오 서비시즈 인코포레이티드 |
염증성 질병의 치료를 위한 치환된 피리딘
|
|
CN115715287A
(zh)
*
|
2020-04-28 |
2023-02-24 |
百时美施贵宝公司 |
作为IL-12、IL-23和/或IFNα调节剂的经取代的N-(甲基-d3)哒嗪-3-甲酰胺或N-(甲基-d3)-烟酰胺化合物
|
|
US20230271942A1
(en)
*
|
2020-08-07 |
2023-08-31 |
Pharmablock Sciences (Nanjing), Inc. |
Cdk9 inhibitor and use thereof
|
|
CN114181257B
(zh)
*
|
2020-09-14 |
2025-02-14 |
四川科伦博泰生物医药股份有限公司 |
吡啶类化合物，包含其的药物组合物，其制备方法及其用途
|
|
JP2023546996A
(ja)
|
2020-10-23 |
2023-11-08 |
ニンバス クロソー， インコーポレイテッド |
Ｃｔｐｓ１阻害剤およびその使用
|
|
US20240076285A1
(en)
*
|
2020-12-16 |
2024-03-07 |
Shankar Venkatraman |
Compounds and compositions for treating conditions associated with sting activity
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
CA3206499A1
(en)
|
2021-02-02 |
2022-08-11 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
MX2023009060A
(es)
|
2021-02-02 |
2023-09-29 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
JP2024506909A
(ja)
|
2021-02-12 |
2024-02-15 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
CA3207819A1
(en)
*
|
2021-02-19 |
2022-08-25 |
Anjali Pandey |
Tyk2 inhibitors and uses thereof
|
|
JP2024508794A
(ja)
*
|
2021-02-19 |
2024-02-28 |
スドー バイオサイエンシーズ リミテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
EP4294806A1
(en)
*
|
2021-02-19 |
2023-12-27 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
US20240189309A1
(en)
*
|
2021-02-19 |
2024-06-13 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
JP2024509192A
(ja)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
CA3214952A1
(en)
|
2021-04-09 |
2022-10-13 |
Silvana Marcel LEIT DE MORADEI |
Cbl-b modulators and uses thereof
|
|
EP4423086A1
(en)
|
2021-10-25 |
2024-09-04 |
Kymera Therapeutics, Inc. |
Tyk2 degraders and uses thereof
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
WO2023108536A1
(en)
*
|
2021-12-16 |
2023-06-22 |
Lynk Pharmaceuticals Co. Ltd. |
Tyk2 inhibitors and compositions and methods thereof
|
|
AU2022412835A1
(en)
|
2021-12-16 |
2024-06-20 |
Lynk Pharmaceuticals Co. Ltd. |
Tyk2 inhibitors and compositions and methods thereof
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|
|
CN116693449A
(zh)
|
2022-03-04 |
2023-09-05 |
上海致根医药科技有限公司 |
用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
|
|
AR129089A1
(es)
*
|
2022-04-19 |
2024-07-17 |
Blueprint Medicines Corp |
Inhibidores de kit
|
|
EP4532485A1
(en)
*
|
2022-05-27 |
2025-04-09 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
AU2023317742A1
(en)
|
2022-08-02 |
2025-03-20 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
CN120019047A
(zh)
|
2022-08-02 |
2025-05-16 |
里米诺生物科学有限公司 |
杂芳基甲酰胺和相关gpr84拮抗剂及其用途
|
|
CN119894873A
(zh)
|
2022-08-02 |
2025-04-25 |
里米诺生物科学有限公司 |
芳基三唑基和相关gpr84拮抗剂及其用途
|
|
WO2024249855A1
(en)
*
|
2023-06-02 |
2024-12-05 |
Idrx, Inc. |
Combination therapy comprising kit inhibitors for use in the treatment of cancer
|
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|